Kana Hashimoto - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer Treated with Concurrent Chemoradiation Therapy by Histological Type

Kazutoshi Toriyama,Makiko Yomota,Maiko Asai,Kana Hashimoto,Kie Mirokuji,Shoko Kawai,Kageaki Watanabe,Kosuke Narita,Yukio Hosomi

INTERNAL MEDICINEno. 20 (2024): 2757-2765

引用0浏览0WOS引用

First-Line Osimertinib for Previously Untreated Patients with NSCLC and Uncommon EGFR Mutations the UNICORN Phase 2 Nonrandomized Clinical Trial

Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe

JAMA oncology（2024）

引用1浏览0WOS引用

Association between tumor mutation burden and oncogenic mutation affecting the immune system of patients with nonsmall cell lung cancer

Takayuki Kobayashi,Makiko Yomota,Masachika Ikegami,Yuji Uehara,Taiki Hakozaki,Kana Hashimoto,Shoko Kawai,Kosuke Narita,Kageaki Watanabe,Yukio Hosomi

ANNALS OF ONCOLOGY (2023): S1416-S1416

引用0浏览0引用

A Study on Oligo-Progression after Durvalumab Plus Platinum- Etoposide for ES-SCLC

Kageaki Watanabe,Kazuhito Misawa,Mao Uematsu,Kana Hashimoto,Yukio Hosomi

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Uncommon EGFR Mutations Conducted with Osimertinib in Patients with NSCLC (UNICORN): A Phase 2 Study

Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

MO31-3 Association between tumor mutation burden and oncogenic mutation affecting the immune system of patients with non-small cell lung cancer

Takayuki Kobayashi,Makiko Yomota,Masachika Ikegami,Yuji Uehara,Taiki Hakozaki,Kana Hashimoto,Shoko Kawai,Kosuke Narita,Kageaki Watanabe,Yukio Hosomi

Annals of Oncology (2023): S1416-S1416

引用0浏览0引用

Association Between the Baseline Tumor Size and Outcomes of Patients with Non-Small Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitor Monotherapy or in Combination with Chemotherapy

Yuji Uehara,Taiki Hakozaki,Rui Kitadai,Kosuke Narita,Kageaki Watanabe,Kana Hashimoto,Shoko Kawai,Makiko Yomota,Yukio Hosomi

Translational lung cancer research（2022）

引用4浏览0WOS引用

P29-5 Efficacy of Immune Checkpoint Inhibition in Patients with Advanced NSCLC with KRAS, MET, Other Minor Driver Alterations

Yuji Uehara,Kageaki Watanabe,Taiki Hakozaki,Kie Mirokuji,Kana Hashimoto,Kosuke Narita,Shoko Kawai,Makiko Yomota,Yukio Hosomi

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)

Yusuke Okuma,Mototsugu Shimokawa,Kana Hashimoto,Hideaki Mizutani,Hiroshi Wakui,Shuji Murakami,Shinji Atagi,Koichi Minato,Masahiro Seike,Yuichiro Ohe,Kaoru Kubota

FUTURE ONCOLOGYno. 5 (2022): 523-531

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn